Viking Therapeutics (VKTX) Stock Price, News & Analysis

$67.00
-2.06 (-2.98%)
(As of 05/17/2024 ET)
Today's Range
$66.68
$71.09
50-Day Range
$62.56
$83.34
52-Week Range
$8.28
$99.41
Volume
4.15 million shs
Average Volume
3.19 million shs
Market Capitalization
$7.39 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$112.38

Viking Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.10 Rating Score
Upside/​Downside
67.7% Upside
$112.38 Price Target
Short Interest
Bearish
10.98% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.88
Upright™ Environmental Score
News Sentiment
0.62mentions of Viking Therapeutics in the last 14 days
Based on 20 Articles This Week
Insider Trading
Selling Shares
$27.12 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.08) to ($1.36) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.50 out of 5 stars

Medical Sector

105th out of 921 stocks

Pharmaceutical Preparations Industry

36th out of 419 stocks

VKTX stock logo

About Viking Therapeutics Stock (NASDAQ:VKTX)

Founded in 2012, Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California. The company is focused on developing novel therapies for metabolic and endocrine disorders, including non-alcoholic steatohepatitis (NASH), hip fracture recovery, and type 2 diabetes. Viking's mission is to bring life-changing treatments to patients with unmet medical needs.

Viking's lead product candidate, VK2809, is a small molecule thyroid beta receptor agonist currently being evaluated in a Phase 2b clinical trial for treating NASH. The company's other product candidates include VK0214, a liver-directed thyroid receptor beta agonist for treating X-linked adrenoleukodystrophy (X-ALD), and VK0612, a novel PPAR-delta agonist for the treatment of type 2 diabetes.

Viking's management team is led by Chief Executive Officer Brian Lian, who joined the company in 2016. Lian has over 25 years of experience in the biotech and pharmaceutical industries, including senior leadership roles at InterMune, Abgenix, and Bristol-Myers Squibb. 

Viking is working hard to grow its revenue. However, the company has yet to turn a profit, reporting a net loss of $68 million in 2022 which increased from 2021's reported $-55 million loss. Viking has also been actively raising capital, recently completing a public offering of common stock.

Viking's current market capitalization is around $1.9 billion, with a price-to-book ratio that aligns with industry peers. Still, some investors see the potential for significant upside if Viking's clinical trials are successful.

Viking's stock price has been volatile over the recent past. The stock has seen a slight uptick recently due to positive news about its drugs in clinical trials. The company's trading volume has been increasing steadily, indicating investor interest.

Viking operates in the highly competitive biotech industry, where companies must navigate complex regulatory environments and rapidly evolving technologies. The NASH market, in particular, is highly competitive, with several large pharmaceutical companies developing therapies for the disease. However, Viking's focus on novel mechanisms of action and expertise in metabolic and endocrine disorders give the company a competitive advantage. Additionally, Viking's partnerships with established biotech companies, such as Ligand Pharmaceuticals and Bayer, provide the company with valuable resources and expertise.

Viking has several potential growth opportunities in the pipeline, including the ongoing Phase 2b clinical trial of VK2809 for treating NASH. If the trial succeeds, Viking could partner with a larger pharmaceutical company to bring the therapy to market. The company's other product candidates, including VK0214 and VK0612, also have the potential to address significant unmet medical needs. Viking has also explored expansion opportunities into new therapeutic areas, such as oncology.

Viking Therapeutics faces a risk from the possibility of regulatory changes affecting the approval of its products. The pharmaceutical industry is heavily regulated, and any changes in regulations or policies could impact Viking's ability to bring its products to market or receive approval for clinical trials. In addition, the company's competitors may also receive approval for similar products, reducing the market share available to Viking.

Risk management is an integral part of any business strategy, and Viking Therapeutics is taking steps to mitigate the risks it faces. The company has a diverse pipeline of products, which helps reduce the impact of any one product failing. Viking is also conducting extensive clinical trials to ensure the safety and efficacy of its products, which could increase the likelihood of approval and reduce the risk of adverse events.

VKTX Stock Price History

VKTX Stock News Headlines

Eli Lilly Gains on the GLP-1 Weight Loss Phenomenon (VKTX)
Eli Lilly stock continues to move higher after the company reported continuing momentum for its flagship GLP-1 weight loss drugs
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
The GLP-1 weight loss trend continues to flourish, and the ante keeps rising. The reigning champions in the battle of the bulge are Novo Nordisk A/V NYSE: NVO with its Semaglutide medications Ozempic and Wegovy, and Eli Lilly & Co. NYSE: LLY with its Tirzepatide medications Mounjaro and Zepbound.
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs? (VKTX)
The GLP-1 weight loss trend continues to flourish, and the ante keeps rising; see how the winner between Wegovy and Zepbound can help your portfolio
Is Viking Therapeutics Stock a Buy?
The 3 Best Russell 2000 Stocks to Buy in May 2024
See More Headlines
Receive VKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viking Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/24/2024
Today
5/18/2024
Next Earnings (Estimated)
7/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VKTX
Fax
N/A
Employees
28
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$112.38
High Stock Price Target
$138.00
Low Stock Price Target
$80.00
Potential Upside/Downside
+67.7%
Consensus Rating
Buy
Rating Score (0-4)
3.10
Research Coverage
10 Analysts

Profitability

Net Income
$-85,890,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$8.47 per share

Miscellaneous

Free Float
105,085,000
Market Cap
$7.39 billion
Optionable
Optionable
Beta
1.12
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Brian Lian Ph.D. (Age 58)
    President, CEO & Director
    Comp: $987.1k
  • Mr. Gregory S. Zante (Age 53)
    Chief Financial Officer
    Comp: $655k
  • Ms. Marianne Mancini (Age 59)
    Chief Operating Officer
    Comp: $670k
  • Mr. Michael Morneau (Age 59)
    Vice President of Finance & Administration
    Comp: $375.33k
  • Dr. Geoffrey E. Barker Ph.D.
    Senior Vice President of Pharmaceutical Development

VKTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Viking Therapeutics stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last year. There are currently 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VKTX shares.
View VKTX analyst ratings
or view top-rated stocks.

What is Viking Therapeutics' stock price target for 2024?

10 brokers have issued 12 month target prices for Viking Therapeutics' stock. Their VKTX share price targets range from $80.00 to $138.00. On average, they predict the company's share price to reach $112.38 in the next year. This suggests a possible upside of 67.7% from the stock's current price.
View analysts price targets for VKTX
or view top-rated stocks among Wall Street analysts.

How have VKTX shares performed in 2024?

Viking Therapeutics' stock was trading at $18.61 at the start of the year. Since then, VKTX shares have increased by 260.0% and is now trading at $67.00.
View the best growth stocks for 2024 here
.

When is Viking Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 24th 2024.
View our VKTX earnings forecast
.

How were Viking Therapeutics' earnings last quarter?

Viking Therapeutics, Inc. (NASDAQ:VKTX) released its quarterly earnings results on Wednesday, April, 24th. The biotechnology company reported ($0.26) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.01. During the same quarter in the previous year, the firm posted ($0.25) earnings per share.

What other stocks do shareholders of Viking Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Viking Therapeutics investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), SCYNEXIS (SCYX), Amarin (AMRN), Advanced Micro Devices (AMD), Verastem (VSTM), Energy Transfer (ET) and Inovio Pharmaceuticals (INO).

When did Viking Therapeutics IPO?

Viking Therapeutics (VKTX) raised $20 million in an initial public offering on Wednesday, April 29th 2015. The company issued 2,500,000 shares at a price of $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO and Feltl and Company was co-manager.

Who are Viking Therapeutics' major shareholders?

Viking Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (7.06%), Avoro Capital Advisors LLC (3.26%), Perpetual Ltd (0.87%), Hood River Capital Management LLC (0.61%), Westfield Capital Management Co. LP (0.60%) and Clearbridge Investments LLC (0.54%). Insiders that own company stock include Brian Lian, Charles A Rowland Jr, Greg Zante, Lawson Macartney, Marianna Mancini, Matthew W Foehr and Sarah Kathryn Rouan.
View institutional ownership trends
.

How do I buy shares of Viking Therapeutics?

Shares of VKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VKTX) was last updated on 5/18/2024 by MarketBeat.com Staff

From Our Partners